Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2022-09-01 00:00:00 ET · period of report 2022-08-31 · accession 0001209191-22-048394 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-01 | 2022-08-31 | KPTI | Mason Michael | EVP, CFO, Treas | A - Grant | $0.00 | +30.0K | 168.5K | +22% | $0 |
| D | 2022-09-01 | 2022-08-31 | KPTI | Mason Michael | EVP, CFO, Treas | A - Grant | $0.00 | +45.0K | 45.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-31 | A | A | 30,000 | $0.00 | 168,509 | D | — | — | (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024. |
| 2 | Derivative | Stock Option (right to buy) | 2022-08-31 | A | A | 45,000 | $0.00 | 45,000 | D | $5.06 · — to 2032-08-30 | 45,000 Common Stock | (F2) This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024. |